Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389810 | 0.88 | GPR119 (0.77) | GPR119CYP2C9 | |
| SCHEMBL386244 | 0.87 | GPR119 (0.79) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL3343620 | 0.85 | GPR119 (0.65) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL386360 | 0.83 | GPR119 (0.62) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL389528 | 0.83 | GPR119 (0.59) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL3343623 | 0.81 | GPR119 (0.59) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4722426 | 0.80 | GPR119 (0.60) | GPR119CYP2C9 | |
| SCHEMBL3343342 | 0.80 | GPR119 (0.59) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL3343283 | 0.80 | GPR119 (0.63) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL5048402 | 0.80 | GPR119 (0.49) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP11B1 | GPR119 31/4885CYP3A4 29/4885CYP2C9 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.